Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study. Trinh JQ, Xiong Y, Smith LM, Abughanimeh O, et al. Anticancer Res 2024;44:605-612.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Trinh JQ, Xiong Y, Smith LM, Abughanimeh O, et al. Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study. Anticancer Res 2024;44:605-612.
PMID: 38307589